Page 139 - 南京医科大学自然版

第45卷第5期 李佳欣，陶善东，于 亮. KMT2A重排急性髓系白血病的研究进展［J］.
2025年5月 南京医科大学学报（自然科学版），2025，45（5）：718-726 ·725 ·

［54］QAZI S，UCKUN F M. Augmented expression of the virus with modulators targeting key signaling pathways［J］.
IL3RA/CD123 gene in MLL/KMT2A⁃rearranged pediatric Mol Cancer，2022，21（1）：196
AML and infant ALL［J］. Onco，2022，2（3）：245-263 ［66］KWON S Y，THI⁃THU NGO H，SON J，et al. Exploiting
［55］CHIARELLA E，ALOISIO A，SCICCHITANO S，et al. bacteria for cancer immunotherapy［J］. Nat Rev Clin
ZNF521 enhances MLL ⁃ AF9 ⁃ dependent hematopoietic Oncol，2024，21（8）：569-589
stem cell transformation in acute myeloid leukemias by ［67］ ZALATAN J G，PETRINI L，GEIGER R. Engineering
altering the gene expression landscape［J］. Int J Mol Sci， bacteria for cancer immunotherapy［J］. Curr Opin Bio⁃
2021，22（19）：10814 technol，2024，85：103061
［56］YI S Q，WRIGHT S，CHE M X，et al. Non⁃canonical tran⁃ ［68］SAIFI O，BREEN W G，LESTER S C，et al. Outcomes of
scription activator activity of RNA ⁃ binding protein patients with R/R B⁃cell NHL and limited（<5 sites）pre⁃
MBNL1 uniquely controls FLT3 expression in MLL⁃rear⁃ CART disease bridged with or without radiotherapy［J］.
ranged leukemias［J］. Blood，2023，142：2760 Blood Adv，2024，8（18）：4877-4885
［57］ ZHOU Y T，QIAN Y，JIN J. Targeting HDAC9 contrib⁃ ［69］XUE F，ZHENG P H，YANG F，et al. Salvage CD20⁃SD⁃
utes to degradation of MLL fusion oncoproteins in KMT2A⁃ CART therapy in aggressive B⁃cell lymphoma after CD19
rearranged acute myeloid leukemia［J］. Blood，2023， CART treatment failure［J］. Front Oncol，2024，14：
142：1578 1376490
［58］JIANG B Q，ZHAO Y M，LUO Y，et al. Outcomes of allo⁃ ［70］DIMA D，DAVIS J，AHMED N，et al. Outcomes of BCMA⁃
geneic hematopoietic stem cell transplantation in adult directed chimeric antigen receptor T⁃cell（CART）thera⁃
patients with acute myeloid leukemia harboring KMT2A py and teclistamab in patients with relapse⁃refractory mul⁃
rearrangement and its prognostic factors［J］. Cell Trans⁃ tiple myeloma with extramedullary disease：a real⁃world
plant，2024，33：9636897231225821 experience of the US myeloma innovations research
［59］LIU L P，ZHANG A L，RUAN M，et al. Prognostic stratifi⁃ collaborative（USMIRC）［J］. Transplant Cell Ther，2024，
cation of molecularly and clinically distinct subgroup in 30（2）：S384-S385
children with acute monocytic leukemia［J］. Cancer Med， ［71］SOOMRO M A，ATRASH S，RASHID A，et al. Outcomes
2020，9（11）：3647-3655 in multiple myeloma patients progressing after BCMA ⁃
［60］ARCECI R J. Novel prognostic subgroups in childhood directed chimeric antigen receptor T cell（CART）thera⁃
11q23/MLL⁃rearranged acute myeloid leukemia：results of py［J］. Transplant Cell Ther，2024，30（2）：S373
an international retrospective study［J］. Yearb Oncol， ［72］KFIR⁃ERENFELD S，ASHERIE N，LEBEL E，et al. Clini⁃
2010，2010：130-131 cal evaluation and determinants of response to HBI0101
［61］ PIGNEUX A，LABOPIN M，MAERTENS J，et al. Out⁃ （BCMA CART）therapy in relapsed/refractory multiple
come of allogeneic hematopoietic stem ⁃ cell transplanta⁃ myeloma［J］. Blood Adv，2024，8（15）：4077-4088
tion for adult patients with AML and 11q23/MLL rear⁃ ［73］SAITO S，NAKAZAWA Y. CAR⁃T cell therapy in AML：
rangement（MLL⁃r AML）［J］. Leukemia，2015，29（12）： recent progress and future perspectives［J］. Int J Hema⁃
2375-2381 tol，2024，120（4）：455-466
［62］ WANG Y，LIU Q F，QIN Y Z，et al. Improved outcome ［74］KIRKEY D C，ROBINSON L，HYLKEMA T，et al. Potent
with hematopoietic stem cell transplantation in a poor and target specific cytotoxicity of PRAME TCR mimic
prognostic subgroup of patients with mixed⁃lineage⁃leuke⁃ CAR T cells in KMT2A⁃rearranged AML patient⁃derived
mia ⁃ rearranged acute leukemia：results from a prospec⁃ xenograft model［J］. Blood，2023，142：4821
tive，multi⁃center study［J］. Am J Hematol，2014，89（2）： ［75］ZHANG X M，LV H R，XIAO X，et al. A phaseⅠclinical
130-136 trial of CLL⁃1 CAR⁃T cells for the treatment of relapsed/
［63］WANG F，FU K，WANG Y J，et al. Small⁃molecule agents refractory acute myeloid leukemia in adults［J］. Blood，
for cancer immunotherapy［J］. Acta Pharm Sin B，2024， 2023，142：2106
14（3）：905-952 ［76］ZHANG H，BU C K，PENG Z Y，et al. Characteristics of
［64］ DUAN L J，WANG Q，ZHANG C L，et al. Potentialities anti ⁃ CLL1 based CAR ⁃ T therapy for children with
and challenges of mRNA vaccine in cancer immunothera⁃ relapsed or refractory acute myeloid leukemia：the multi⁃
py［J］. Front Immunol，2022，13：923647 center efficacy and safety interim analysis［J］. Leukemia，
［65］ ZHU Z，MCGRAY A J R，JIANG W J，et al. Improving 2022，36（11）：2596-2604
cancer immunotherapy by rationally combining oncolytic ［77］MA Y J，DAI H P，CUI Q Y，et al. Successful application